<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03122028</url>
  </required_header>
  <id_info>
    <org_study_id>LA-EU-01</org_study_id>
    <nct_id>NCT03122028</nct_id>
  </id_info>
  <brief_title>Clinical Investigation of the LAmbre Left Atrial Appendage Closure System</brief_title>
  <official_title>A Prospective, Non-Randomized, Multi-Center, Open-Label, Non-Comparative, Interventional Clinical Investigation of the LAmbre Left Atrial Appendage Closure System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lifetech Scientific (Shenzhen) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lifetech Scientific (Shenzhen) Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study LA-EU-01 was to examine the safety and the feasibility of the LAmbreTM&#xD;
      Left Atrial Appendage Closure System in patients with non-valvular paroxymal, persistent or&#xD;
      permanent atrial fibrillation, by using imaging approaches, i.e. combined trans-esophageal&#xD;
      and transthoracic echocardiography.&#xD;
&#xD;
      The conducted LA-EU-01 study was a prospective, non-randomized, multi-center, open-label,&#xD;
      non-comparative, interventional clinical investigation with the participation of two clinical&#xD;
      centers in Germany and the inclusion of 61 subjects.&#xD;
&#xD;
      Participating subjects were patients with non-valvular paroxymal, persistent or permanent&#xD;
      atrial fibrillation with long-term sustainability and scheduled for interventional closure of&#xD;
      the left atrial appendage who could not be treated with anticoagulation.&#xD;
&#xD;
      After the procedure of implantation of the LAmbreTM Left Atrial Appendage Closure System,&#xD;
      patients underwent a first follow up assessment prior to hospital discharge then at 30 days,&#xD;
      6 and 12 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 5, 2013</start_date>
  <completion_date type="Actual">November 9, 2016</completion_date>
  <primary_completion_date type="Actual">March 9, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>Absence of device or procedure related serious adverse events at 6 months after device implantation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stable device placement</measure>
    <time_frame>6 months</time_frame>
    <description>Stable device placement in left atrial appendage as assessed by transesophageal echocardiogram (TEE) at 6 months after device implant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Residual jet flow</measure>
    <time_frame>6 months</time_frame>
    <description>Successful sealing around the device at the LAA orifice (residual jet flow of &lt; 5 mm) as measured by transesophageal echocardiogram (TEE) at 6 months after device implant</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>LAmbre closure system</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LAA closure system</intervention_name>
    <description>Patients with non-valvular paroxymal, persistent or permanent atrial fibrillation with long-term sustainability and cannot be treated with anticoagulation and scheduled for interventional left atrial appendage closure.</description>
    <arm_group_label>LAmbre closure system</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Patients scheduled for interventional closure of the left atrial appendage (LAA) due&#xD;
             to a high thromboembolic risk and cannot be treated with anticoagulation.&#xD;
&#xD;
          -  Chronic atrial fibrillation ≥3 months; paroxysmal, persistent or permanent nonvalvular&#xD;
             Atrial Fibrilation (AF)&#xD;
&#xD;
          -  CHA2DS2 -VASC score 2 or higher&#xD;
&#xD;
          -  Eligible for clopidogrel and aspirin&#xD;
&#xD;
          -  Able to understand the requirements of the study and willing to follow study&#xD;
             instructions, provide written informed consent, and agree to comply with all study&#xD;
             requirements, including the required study follow-up visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of rheumatic, degenerative or congenital valvular heart diseases&#xD;
&#xD;
          -  Presence of rheumatic, degenerative or congenital valvular heart diseases&#xD;
&#xD;
          -  The diameter of left atrium ≥65 mm&#xD;
&#xD;
          -  LAA Ostium &lt; 12mm or &gt; 30 mm&#xD;
&#xD;
          -  Prior surgical removal of Left atrium&#xD;
&#xD;
          -  Prior heart transplant&#xD;
&#xD;
          -  Symptomatic patients with carotid artery disease (such as carotid stenosis ≥ 50%)&#xD;
&#xD;
          -  Recent or acute myocardial infarction (MI) or unstable angina (recent is defined as&#xD;
             within 3 months of implant date)&#xD;
&#xD;
          -  Decompensated heart failure (NYHA grade III-IV)&#xD;
&#xD;
          -  Patients have an electrophysiological ablation procedure planned within 30 days of&#xD;
             potential the LAmbreTM Left Atrial Appendage Closure System implant date&#xD;
&#xD;
          -  Patients have a planned electrophysiologic 30 days post implantation of the LAmbreTM&#xD;
             Left Atrial Appendage Closure System&#xD;
&#xD;
          -  Patients have a planned cardioversion 30 days post implantation of the LAmbreTM Left&#xD;
             Atrial Appendage Closure System&#xD;
&#xD;
          -  Patients with a history of heart valve replacement operation with an mechanical&#xD;
             prosthesis&#xD;
&#xD;
          -  History of stroke or Transient Ischemic Attack (TIA) within 30 days&#xD;
&#xD;
          -  Have thrombocytopenia (platelet ≤ 100.000 platelets per microliter (mcL))&#xD;
&#xD;
          -  Heart rate in rest &gt; 110 beats per minute (BPM)&#xD;
&#xD;
          -  A single episode of transient atrial fibrillation&#xD;
&#xD;
          -  Pericardial effusion &gt; 5mm pre-procedural&#xD;
&#xD;
          -  Presence of active sepsis or endocarditis&#xD;
&#xD;
          -  Cardiac tumors or other malignancy with estimated life expectancy less than 2 years&#xD;
&#xD;
          -  Patients who are pregnant, breastfeeding, or desires to become pregnant during the&#xD;
             course of the study&#xD;
&#xD;
          -  Participation in the other investigational trials in which the primary endpoint is not&#xD;
             met yet&#xD;
&#xD;
          -  Subject dependency of the Sponsor, of the institution in which the trail is conducted,&#xD;
             or of the investigator&#xD;
&#xD;
          -  Investigator expectation that the patient will not be able to complete the trial&#xD;
             according to the requirements&#xD;
&#xD;
          -  A known allergy to nitinol Esophageal ultrasonic exclusion criteria&#xD;
&#xD;
          -  LVEF ≤ 30 %&#xD;
&#xD;
          -  Presence of thrombus in the left atrial appendage (LAA)&#xD;
&#xD;
          -  Patent Foramen Ovale (PFO) with history of paradoxical embolism&#xD;
&#xD;
          -  Mitral valve stenosis (Mitral valve area ≤ 2 cm2)&#xD;
&#xD;
          -  Presence of complex aortic plaque (≥4mm) in ascending aorta&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Horst Sievert</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cardiovascular Center</affiliation>
  </overall_official>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>April 17, 2017</study_first_submitted>
  <study_first_submitted_qc>April 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2017</study_first_posted>
  <last_update_submitted>April 19, 2017</last_update_submitted>
  <last_update_submitted_qc>April 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LAmbre</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

